PARTICULARS TO APPEAR ON THE OUTER PACKAGE - CARTON

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Droncit tablets 50 mg.

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains 50 mg praziquantel.

3. PACKAGE SIZE

20 tablets
24 tablets
48 tablets
100 tablets
104 tablets

4. TARGET SPECIES

Cats and dogs

5. INDICATIONS

For the elimination of tapeworms (including *Echinococcus* spp.)

6. ROUTES OF ADMINISTRATION

Oral use. 1 tablet per 10 kg.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.
Keep the blister pack in the outer carton.
Store in a dry place.
Any unused half tablet should be discarded.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Vetoquinol UK Limited

14. MARKETING AUTHORISATION NUMBERS

Vm 08007/5015

15. BATCH NUMBER

Lot {number}

Droncit should not be administered to unweaned kittens and puppies, as such animals are rarely infected with tapeworms.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS - BLISTER STRIPS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Droncit

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Praziquantel 50mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}



Vetoquinol logo

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Droncit tablets 50mg

2. Composition

Each tablet contains:

(Active substance:)

Praziquantel 50 mg

White tablets with a score line on one side, which can be divided into halves.

3. Target species

Dogs and cats

4. Indications for use

Uses

For the treatment of adult tapeworms. The veterinary medicinal product is effective against both immature and mature forms of adult tapeworms in both cats and dogs. The veterinary medicinal product is a highly effective treatment against all the common species of tapeworm infecting cats and dogs in the United Kingdom and Ireland including:

Echinococcus granulosus,
Taenia multiceps, Taenia hydatigena,
Taenia ovis, Taenia pisiformis
Taenia taeniaeformis, Dipylidium caninum.

The veterinary medicinal is also effective against *Echinococcus multilocularis* (see Special warnings).

5. Contraindications

Do not use in dogs weighing less than 2.5 kg.

Do not use in unweaned kittens and puppies, as such animals are rarely infected with tapeworms.

6. Special warnings

Fleas serve as intermediate hosts for one common type of tapeworm - *Dipylidium caninum*. To avoid reinfection with this parasite, flea control of the animal and its housing should be carried out at the same time. Unless flea control is complete an infected flea population may survive: i.e. re-treatment of the animal may be necessary.

As a precautionary measure to prevent establishment of *E. multilocularis* in the UK and Ireland it is recommended that all dogs and cats entering the country be treated with praziquantel.

Special precautions for safe use in the target species:
Any unused half tablet should be discarded.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In the interests of good hygiene persons administering the tablets directly to the animal or adding them to the animal's food should wash their hands afterwards.

7. Adverse events

Target species: Dogs and cats

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation using the contact details at the end of this leaflet, or via your national reporting system at:

Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Dosage

Oral use

5 mg/kg body weight (1 tablet per 10 kg body weight).

Dogs	2.5 to 5 kg	½ tablet
	Greater than 5 to 10 kg	1 tablet
	Greater than 10 to 15kg	1 ½ tablets
	Greater than 15 to 20 kg	2 tablets
	Greater than 20 to 25 kg	2 ½ tablets
	Greater than 25 to 30 kg	3 tablets
	Over 30kg *pro rata*	For each additional 5kg bodyweight, administer an additional half tablet
Cats	Adult cats	½ tablet

9. Advice on correct administration

The tablets are administered by opening the animal's mouth and pushing the tablet over the back of the tongue so that it cannot be rejected. Alternatively, a tablet can be wrapped in a piece of meat or butter and offered to the animal or crushed and mixed with the food.

A single dose is all that is required. However, for dogs in rural areas and for packs of hounds, this dose should be repeated every four weeks to ensure that newly acquired tapeworms are destroyed before reaching maturity. Dosing must be associated with strict control of the dog's diet to ensure that uncooked offal is not eaten.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 25 °C.
Keep the blister pack in the outer carton.
Store in a dry place.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister pack after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary Medicinal Product not subject to prescription

14. MARKETING AUTHORISATION NUMBER AND PACK SIZES

Vm 08007/5015

Pack sizes:
20 tablets (2 blister packs with 10 tablets each)
24 tablets (3 blister packs with 8 tablets each)
48 tablets (6 blister packs with 8 tablets each)
100 tablets (10 blister packs with 10 tablets each)
104 tablets (13 blister packs with 8 tablets each)

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Vetoquinol UK Limited,
Steadings Barn,
Pury Hill Business Park, Nr. Alderton,
Towcester,
Northamptonshire,
NN12 7LS

Manufacturer responsible for batch release:

- KVP Pharma + Veterinär Produkte GmbH, Projensdorfer Str. 324, 24106 Kiel, Germany
- Vetoquinol S.A., Magny-Vernois, 70200 Lure, France

17. Other information

AVM-GSL

Gavin Hall
Approved: 03 June 2026